1. Scrip
  2. >>Conferences
  3. >>BIO

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

Dealmaking Has Become A Cash Alternative

 
• By Mandy Jackson

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Declining biotech valuations are not expected to reverse course soon (Shutterstock)
Key Takeaways
  • With a slowdown in venture capital funding and a closed IPO window, companies are struggling to raise money in 2025 and financial market conditions are not expected to improve soon.

Both private and public biopharmaceutical companies are struggling to raise fresh capital for ongoing research and development programs, despite expectations...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from BIO

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

 
• By Mandy Jackson

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.